| Document Date: 2014-01-09 11:14:02
Open Document File Size: 875,90 KBShare Result on Facebook
City Ingelheim / / Company Bayer / miRNAs (e.g. isolated from exosomes) Only CTCs / Eli Lilly / / Currency EUR / / IndustryTerm pharmaceutical industry / technology development / established close-to-the-market technologies / pharmaceutical / concrete technologies / / MedicalCondition tumor / cancer / molecular disease / tumour / early disease / / MedicalTreatment oncology therapies / / Organization EFPIA / FDA / Advisory Board / / Person Thomas Schlange / / / Position cost driver in drug development / / Technology bioinformatics / close-to-the-market technologies / promising concrete technologies / selected technologies / Stem Cells / drug development / / URL http /
SocialTag |
Blood-based biomarker assays for personalised tumour therapy: value of latest circulating biomarkers Thomas Schlange, Bayer HealthCare Need for public-private